Monday, 13th November Clinical Oncology Society of Australia Annual Scientific Meeting 2017

Dana Rollison
How we develop and use health data systems to support clinician decision making and research in cancer is a national priority. This workshop will explore this topic through a discussion with national and international leaders from both a technical, governance and clinical perspective. You will take away from the workshop an understanding of where we are at and how all the pieces of this complex jigsaw puzzle can fit together.

Welcome by COSA President
Welcome to Country by local Indigenous group
Official opening by His Excellency General The Honourable David Hurley AC DSC (Ret'd), Governor of New SouthWales

• Overview and history of immunotherapy - Jonathan Cebon
• 3-year overall survival for patients with advanced NSCLC treated with pembrolizumab - Matthew D. Hellmann
• Shaping patient expectations of treatment and medicine - Ian Kerridge

• Radiation dose-fractionation influences the immune modulatory effects of radiotherapy and anti-cancer activity of checkpoint blockade therapy. - Nicole M Haynes
• Current clinical trials investigating integration of immune therapy and radiotherapy: Focus on ablative radiotherapy combinations - Shankar Siva
• Integrating immunotherapy and stereotactic radiosurgery in the management of patients with brain metastases - Mark Pinkham
• Cranial Radiosurgery and immune therapy. Should we be concerned re toxicity? - Brindha Shivalingam
• Immunosuppression and immunotherapy: Who to rob - Peter or Paul? - Mark Shackleton

• Outcomes of complex cancer surgery in Queensland - Mark Smithers
• Variations in breast cancer management: Identifying outliers and how to address them - Colin Furnival
• The value of a population-wide audit: Queensland Colorectal Cancer Audit 2012 and 2014 - Nicholas Lutton
• Population-wide treatment data informs clinical management of lung cancer in Queensland - Margot Lehman

• Assessing the benefits of anticancer drugs: update on the ASCO and ESMO value framework - Nicola Lawrence
• Public perception of value with immunotherapy - Richard Vines
• Disinvestment from low-value cancer care: Part of the next quality frontier - Adam Elshaug
• Assessing the cost-effectiveness of immunotherapy: Do modern drugs need modern methods? - Richard De Abreu Lourenco

• To err is human... prescribing errors in cancer treatment - Dorothy M Keefe
• A Sydney Hospital’s experience in response to a Chemotherapy dosage controversy - Robert Thomas
• Peer Review -improving performance in practice. - Matthew J Links
• Standards, Governance and ICT: the holy trinity for systemic therapies? - Maree Bransdon
• Making Medicine Safe – Lessons from Boeing, Hopkins & Tom Hanks - Anthony Joshua

Panel Discussion 

• Integrating psychosocial care into cancer services: The path from evidence to implementation - Brian Kelly
• PROMPT-Care: A fully integrated eHealth system to support patient-centred cancer care and self-management - Afaf Girgis
• Making screening, assessment, referral and management of anxiety and depression in cancer care a reality: developing a system addressing barriers and facilitators to support sustainable implementation   - Heather Shepherd

• Education needs of health professionals caring for adolescents and young adults with cancer - Natalie Bradford
• A randomised controlled trial of a treatment decision-aid for asymptomatic women with rising CA-125 after successful first line therapy for ovarian cancer - Ilona Juraskova
• Implementing Pathways for Cancer Early Detection (I-PACED): Identifying systems level issues in primary care - Amber Kelaart
• Evaluation of an online communication skills training programme for oncology health care professionals working with culturally and linguistically diverse patients - Bettina Meiser
• Identifying and responding to anxiety and depression in adult cancer patients: Pilot testing of an on-line communication skills education program targeting challenging conversations for oncology health professionals - Joanne Shaw

• Quality: Proactive or Reactive? - An Australian Perspective - Clifford Hughes
• Evolution of Quality Based Medicine:  How do we get from reactive to proactive? - Monika Krzyzanowska
• Creating learning systems for quality and safety in cancer care - Carrie Marr
• Quality - Proactive or Reactive (A Consumer Perspective) - Grant Mundell

• BROCADE:  The National Breast Cancer Foundation repository of primary tumours and metastases from breast cancer patients - Robin L Anderson
• A novel colorectal cancer risk prediction tool (CRISP): from inception to implementation. - Jon Emery
• Small Animal Radiation Research Platform (SARRP): Aiding the optimisation of combined therapy for brain cancer - Kelly McKelvey
• PD-L1 expression on circulating epithelial tumor cells (CETCs) is associated with immune evasion and tumor progression in breast cancer patients and differs from PD-L2 expression - Daniel Lux
• Using a multidisciplinary meeting to provide contemporaneous breast cancer data - June Rose
• A novel combination therapy that re-instates the therapeutic efficacy of doxorubicin via lysosomal permeabilisation using Dp44mT or DpC - Nicole A Seebacher
• Effects of a laxation and probiotic bowel preparation regimen: A randomized controlled trial in patients undergoing prostate radiation therapy. - Nicole Weston
• Accuracy of Cockcroft-Gault (CG) Calculation of Glomerular Filtration Rate (GFR) in comparison to chromium 51-EDTA in a community oncology setting. - Suzanne Allan
• Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab in patients with melanoma who progressed during prior anti–PD-1/PD-L1 therapy - Jamie Lopez
• Identification of inflammatory markers of chemoradiotherapy-induced gastrointestinal toxicity in aesophageal cancer - Joanne Bowen
• A phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results - John Bower
• Single-agent dose-finding cohort of a phase 1/2 study of lenvatinib in children and adolescents with refractory or relapsed solid tumors - John Bower
• Phase 3 trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC) - John Bower
• Preliminary results of a phase 1/2a study of BMS-986156 (glucocorticoid-induced tumor necrosis factor receptor–related gene [GITR] agonist), alone and in combination with nivolumab in patients with advanced solid tumors - Matteo S Carlino
• Retrospective analysis of clinical characteristics and outcomes for patients enrolled on oncology phase 1 clinical trials at Liverpool Hospital Cancer Therapy Centre - Emma Carson
• Prognostic significance of pre-treatment neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in glioblastoma - Giovana Celli Marchett
• Patterns of Post-Mastectomy Radiotherapy in Women with T_1-2N₁ Breast Cancer in South Western Sydney - Amrita Chandra
• Patient preferences for axillary dissection in sentinel lymph node positive early breast cancer - David WS Chang
• Lung adenocarcinoma with frank maelena at initial presentation - utility of capsule endoscopy to discovery miliary small bowel metastases - Timothy Clay
• The detection of secondary lower limb lymphedema in women following treatment for gynaecological cancer.   - Wendy Dawson
• General characteristics, patterns of relapse and treatment outcomes of patients with HER2 amplified metastatic breast cancer (MBC) who are hormone receptor positive (HR+) versus hormone receptor negative (HR-) - Monica I Dumbrava
• The CHEST Australia Trial: a Phase II randomised controlled trial of an intervention to reduce time to consult with symptoms of lung cancer. - Jon Emery
• Systemic therapy clinical trial recruitment of melanoma patients who live a long-distance from a tertiary referral centre - Elizabeth S Emmett
• Retrospective Single Institution Audit of the tolerability and efficacy of Enzalutamide in patients with Castrate Refractory Metastatic Prostate Cancer in a Community Oncology setting - James Fletcher
• Assessing Treatment Tolerability After Geriatric Assessment in The Senior Oncology Clinic at the Gold Coast University Hospital - James Fletcher
• Phase 1b/2 study to evaluate eribulin mesylate (ERI) in combination with pembrolizumab (PEM) in patients with metastatic triple-negative breast cancer (mTNBC) - Mile Janevski
• A randomized, open-label, multicenter phase 1b/2 study of eribulin mesylate in combination with PEGylated recombinant human hyaluronidase in patients (pts) with HER2–negative, high-hyaluronan metastatic breast cancer (MBC) - Mile Janevski
• Utilization and outcomes of eribulin in triple-negative metastatic breast cancer (TN MBC): real-world findings - Mile Janevski
• The effect of immune genetic variants on chemotherapy-induced gastrointestinal toxicity (CIGT) risk in patients receiving 5-fluorouracil. - Samantha K Korver
• Interleukin-1 beta (IL1B) genetic variability is predictive of chemotherapy-induced gastrointestinal toxicity (CIGT) risk in patients receiving 5-fluorouracil. - Samantha K Korver
• A pilot study to evaluate the clinical utility of the Cancer and Aging Research Group (CARG) prediction tool for treatment related toxicity in patients over 70 years of age undergoing systemic therapy at St Vincent’s Hospital, Melbourne. - John Lai
• ADT in prostate cancer patients: prevention of adverse effects using a 6-month home-based progressive resistance training program - Teresa Lam
• Chinese women with triple negative breast cancers have a better clinical outcome - Aric WZ Lee
• Investigating the association between intra-tumoral and systemic immune biomarkers and long term survival outcomes in pancreatic adenocarcinoma - Belinda Lee
• Capecitabine and nab-paclitaxel as second-line treatment for advanced biliary tract cancer (ABTC): Results from a phase II pilot study - Carly Leighton
• Case series: Prevention and management of carcinoid crises in high-risk neuroendocrine patients undergoing Peptide Receptor Radioligand Therapy (PRRT) - Minmin Li
• Echocardiography has low utility in cancer patients with Staphylococcus aureus bacteraemia - Zoe Loh
• A decade of G-CSF prescribing during curative chemotherapy for early breast cancer: what trends are changing? - Zoe Loh
• Tumour characteristics and treatment patterns in relapsed metastatic Her2 positive breast cancer - Sheau Wen Lok
• A comparison of two different approaches to the treatment of stage I testicular cancers after orchidectomy: active surveillance versus adjuvant chemotherapy   - Ali Mahani
• Regional differences in the phase 3 METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC) - Paul Mainwaring
• Predictive Value of Early Prostate Specific Antigen (PSA) Response in Patients with Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Treated with Post-Docetaxel Abiraterone - Andrew Mant
• The effects of exercise training on neurophysiology, symptoms, and function in cancer survivors with chemotherapy-induced peripheral neuropathy - J. Matt McCrary
• A retrospective audit of outcomes of carboplatin/paclitaxel chemoradiation for esophageal cancer - Rita McMorrow
• Incidence of unplanned admissions during chemoradiotherapy for head and neck and lung cancers. - Siddharth Menon
• Characterizing acute ward admissions of advanced cancer patients to the Royal Brisbane Hospital - Dolly Dr Mittal
• Predicting chemotherapy toxicity in older adults: comparing the value of the CARG Toxicity Score with oncologists’ estimates of toxicity - Erin B Moth
• Real-world survival data in metastatic melanoma in Western Australia between 2009-2016. - Arthur Mulvey
• Rates of peripheral neuropathy (PN) in patients with relapsed and refractory multiple myeloma (RRMM) treated with carfilzomib vs comparators in pivotal Phase 3 trials - Kristy Shipman
• A review of the optimal cancer care pathway for high grade glioma in Tasmania – An opportunity for improved patient and carer outcomes. - Rachel E Nimmo
• Second-line chemotherapy for malignant pleural mesothelioma (MPM): Patterns of care in two Australian tertiary institutions - David Palmieri
• Symptomatic improvement of vulvovaginal atrophy in breast cancer patients using vaginal laser therapy: report from LAAVA pilot study. - Antonia Pearson
• Demonstrating differences between clinical trial data and real world data (RWD) in metastatic castration-resistant prostate cancer (mCRPC) - Christine Semira
• Population-Based Glioblastoma Treatment Outcomes - Graham Pitson
• Screening for Circulating Tumour Cells allows early detection of cancer and monitoring of treatment effectiveness: an observational study of 600 patients - Karin Ried
• Colorectal cancer in a large rural centre: an audit of timeliness to initiation of adjuvant chemotherapy in Dubbo - Joel D Riley
• Characterization of complete responses (CRs) in patients with advanced melanoma (MEL) who received the combination of nivolumab (NIVO) and ipilimumab (IPI), NIVO, or IPI alone - Rosemary Hemaya
• Advocating to address inequity in research funding for low survival cancers - Esther Sadek
• How do cancer patients use the term resilience? A systematic review of qualitative studies - Wei Son Tan
• Accuracy and prognostic significance of oncologists’ estimates and scenarios for survival time in a randomised phase 2 trial of regorafenib in advanced gastric cancer. - Anuradha Vasista
• Can time to progression on last line treatment inform us about post-progression survival time in advanced gastric cancer? - Anuradha Vasista
• Delays in lung cancer referral pathways between rural and urban patients in North Queensland: A mixed methods study - Rishabh Verma
• Impact of duration of dose interruption on the efficacy of lenvatinib (LEN) in a phase 3 study in patients (pts) with radioiodine refractory differentiated thyroid cancer (RR-DTC) - Louise Young
• A basket study of apatinib induced tumor cavitation and CEA increase in multiple solid tumors - Xiaochun Zhang
• Retrospective review of potential immune activity of complementary medicines taken by patients undergoing treatment with immunotherapy - Sally Brooks
• Survival of uveal melanoma patients treated with combination and single agent immunotherapy. - Reece Caldwell
• Characterization of potential predictive biomarkers of response to nivolumab in CheckMate 141 in patients with squamous cell carcinoma of the head and neck (SCCHN) - Diana Nazemian-Pour
• The changing role of the cancer nurse – Enabling patients to self-manage their immunotherapy treatments - Lorna Cook
• The experience of patients receiving pembrolizumab therapy for metastatic melanoma - Haryana Dhillon
• Three-year follow-up from checkMate 017/057: Nivolumab versus Docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) - Jamie Lopez
• Nivolumab vs Investigator’s Choice (IC) in patients with Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN): efficacy and safety in checkMate 141 by Prior cetuximab use - Diana Nazemian-Pour
• Nivolumab vs investigator’s choice (IC) for platinum-refractory recurrent or metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN; checkmate 141): Outcomes in first-line R/M patients and updated safety and efficacy - Diana Nazemian-Pour
• Patterns of immunotherapy use and management of toxicities in regional and tertiary settings - Brett Hamilton
• Real-world experience and challenges of immunotherapy at a regional Victorian Hospital - Jia Hao Hui
• Clinical activity, patient-reported outcomes, and safety with durvalumab after chemoradiation in locally advanced, unresectable NSCLC: PACIFIC study - Rina Hui
• Outcomes of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) in a Regional australian population - Lawrence Kasherman
• Utility values across lines of therapy in immuno-oncology treatments: an example from advanced melanoma - Hansoo Kim
• Cost effectiveness analysis (CEA) of nivolumab in 2nd line non-small cell lung cancer (NSCLC) with non-squamous histology (NSQ) using a mixed comparator of docetaxel and pemetrexed in an Australian setting - Hansoo Kim
• Cost utility analysis (CUA) of nivolumab compared to everolimus for the treatment of metastatic renal cell carcinoma (RCC) in Australia - Hansoo Kim
• A single institutional experience of immune checkpoint inhibitors in the treatment of advanced mucosal melanoma - James C Kuo
• A supportive care intervention for people with metastatic melanoma treated with immunotherapy: a pilot study assessing feasibility and perceived benefit. - Judith Lacey
• Understanding real-world patients’ experience on pembrolizumab, anti-programmed death 1 monoclonal antibody (anti-PD1), for advanced melanoma: a qualitative study - Donna Milne
• A case of metastatic urothelial cancer responds to nivolumab - Kimberley S Minas
• Early immunotherapy-related adverse events: Do they predict response in melanoma and lung cancer? - Geoffrey D Peters
• Nivolumab in patients with previously treated metastatic squamous non-small cell lung cancer (NSCLC): Results of a European single-arm, phase 2 trial (CheckMate 171) including patients aged ≥70 years or with poor performance status - Kelley Palmer
• Evaluating the Economic Burden of Checkpoint Inhibitor-Induced Autoimmune Colitis - Zainab Reslan
• Efficacy and toxicity of immunotherapy in cancer patients with poor performance status - Marty Tio
• Stabilisation of Alveolar Soft Part Sarcoma with Pazopanib as single agent therapy and renewed effects post therapy break   - Roderick Walker
• Spectrum, incidence, management and outcomes of severe immune-related adverse events (irAEs) in patients admitted to a tertiary referral hospital - Helen Westman
• Large joint inflammatory arthritis induced by pembrolizumab in metastatic melanoma - Vanessa Wong
• A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with endometrial carcinoma - Louise Young
• A phase 1b/2 trial of lenvatinib+pembrolizumab in patients with renal cell carcinoma - Louise Young
• Retrospective audit of patients in Royal Darwin Hospital (RDH) with metastatic colorectal carcinoma (mCRC): To observe whether first line treatment response predicts prognosis and response to subsequent lines of therapy. - Khobe K.C Chandran
• Don't let me be misunderstood! Improving communication during chemotherapy for patients from CALD (culturally and linguistically diverse) backgrounds. - Deirdre C D'Souza
• Survivors teaching students: Saving women’s lives® - an ovarian cancer learning initiative for medical and health professional students. - Helen Gooden
• Can you still show care with a quickie?: Multi-disciplinary health professionals’ experience of a one-day communication skills workshop compared to an express two-hour workshop - Lyndal Gray
• Use of simulated patients and experiential learning to induct nurses providing phone-based cancer information and support - Katherine Lane
• The positive impact of a cancer malnutrition eLearning program - Jenelle Loeliger
• Evaluating immunotherapy education for melanoma patients. - Lydia Visintin
• Tears, tantrums and training - do we have the time? Communicating Actively Responding Empathically (CARE): Comparison of communication training workshops for health professionals working in cancer care - Jodie Nixon
• Clinical Characterisation of Checkpoint inhibitor induced rashes – a CNC perspective - Nicole Taylor
• The usability study of workshop to spread screening triage program regarding to cancer patients’ distress  - Megumi Uchida
• Putting the ‘S’ in STaR: Collection of population-level registry derived cancer stage at diagnosis (RD-Stage) as part of the Stage, treatment and recurrence (STaR) project - Robert Long
• Retrospective analysis of concomitant medications and overall survival in metastatic breast cancer patients using data from Project Data Sphere - Emma Carson
• Breast conserving surgery and radiation therapy: Queensland's experience - Nathan Dunn
• Adjuvant therapy in node positive breast cancer patients - Nathan Dunn
• Regional multidisciplinary service for lung cancer: Gippsland experience - Shafaet Jamil
• Pre-diagnosis smoking status and risk of second primary cancer in cancer survivors : National Health Insurance Corporation Study - JIHYE JUN
• Retrospective analysis of thoracic oncology at Monash Health 2016-2017 specifically investigating prevalence of EGFR mutated lung cancer - Christine Muttiah
• Timeliness in Lung Cancer care: A Scoping Review - Sharon Nahm
• Predictors of health status in South Australians caring for people with cancer: a population-based study - Jane Phillips
• Demographic and health system factors associated with prostate specific antigen testing in Australians: Linked data analysis from the New South Wales 45 and Up Study - David Smith
• ‘Bridging the continuum’ – Reporting population-level trends across the continuum of care: The National Cancer Control Indicator (NCCI) framework - Alan Woods
• The TRITON clinical trial programme: evaluation of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD) - Laurence Krieger
• Evaluation of Bortezomib use in Queensland public hospitals for the treatment of multiple myeloma - Ian McPherson
• Pilot and definitive randomised double-blind placebo-controlled trials evaluating an oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting (CINV) - Antony Mersiades
• Idronoxil levels of patients receiving NOX66 - an open label phase 1a PK study - Ian Minns
• ENOX2 levels of patients receiving NOX66 in an open label phase 1a PK Study - Ian Minns
• Safety of NOX66 in combination with palliative dose radiotherapy – a phase 1 dose escalation study - Ian Minns
• AGITG NABNEC:  A Randomised Phase II Study Of nab-paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas. - Uzma Rayani
• The “Hair Spare” study - A feasibility study of hair sparing whole brain radiotherapy for brain metastases with volumetric modulated arc therapy (VMAT). - Narelle Williams
• Changes in adjuvant systemic therapy over 10 years of follow up on ANZMTG 01.07 TROG 08.05 Whole Brain Radiotherapy in Melanoma (WBRTMel) randomised controlled trial (RCT) - A case series of 100 patients with 1-3 brain metastases from melanoma. - Narelle Williams
• P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours (GCTs) - Nicole Wong
• A phase 3 trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab vs sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma (RCC) - Louise Young

• Telehealth for cancer care: challenges and opportunities - Danette H Langbecker
• Does it matter who addresses the psychosocial issues as long as someone does? - Afaf Girgis
• Integration of online therapy for anxiety and depression into routine cancer care - Joanne Shaw
• Facilitating effective family involvement in cancer care: Clinical practice guidelines and online clinician training - Ilona Juraskova

• Systemic therapy as treatment for Queensland colorectal cancer patients - Nathan Dunn
• Combining analysis of solid and liquid biopsy: insights into tumor heterogeneity - Jean-Francois Laes
• The associations between variants in pigmentary genes, and serum prostate specific antigen levels: Results from the Concord Health and Ageing in Men Project. - Visalini Nair-Shalliker
• Can ERBB4 induce nuclear YAP in High Grade Glioma? - Samad Raza

• Just as I expected: The impact of pre-treatment response expectancies of radiotherapy toxicities - Elise J Devlin
• Overall survival (OS) in METEOR, a randomised phase 3 trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma (RCC) - Paul Mainwaring
• Application of clinical guidelines in the management of small cell lung cancer - Kate Wilkinson
• Is mental well-being influenced by masculine self-esteem in men with prostate cancer? A cross-sectional study. - Eva M Zopf

• Mucinous ovarian cancers of uncertain primary (MO-CUP) - does the site of origin really matter? - Nicola S Meagher
• The Cancer Stem-Like Cell Marker SOX2 is Prognostic and May Predict Response to Chemotherapy in Colon Cancer - Tim J Miller
• Budesonide reduces neratinib-induced gastrointestinal injury and diarrhoea in rats - Kate R Secombe
• Detection of Plasma Colorectal Cancer Prognostic Biomarkers - Charlie, Seong Beom Ahn
• Supervised on-site exercise during acute radiation treatment: effect on muscle strength, physical function and body composition. - Favil Singh

• Avoiding whole brain radiation therapy for brain metastases in the era of targeted therapies and immunotherapy. - Michael Back
• Progression after the next line of therapy (PFS2) and updated OS among patients with advanced NSCLC and PD-L1 tumor proportion score (TPS) ≥50% enrolled in KEYNOTE-024. - Rina Hui
• CNS response to osimertinib in patients (pts) with T790M-positive advanced NSCLC: Data from a randomized phase III trial (AURA3) - Thomas John
• Priority-driven Collaborative Cancer Research Scheme (PdCCRS) – 10 year look back - Gayle Jones
• Patterns of multiple immunohistochemical biomarker expression predict survival after resection in pancreatic ductal adenocarcinoma: a retrospective cohort study and two-step cluster analysis. - Christopher B Nahm

• An Overview of the Management of Gastrointestinal Toxicities from Checkpoint Inhibitors     - Stephen J Tattersall
• An Endocrinologist’s View: Diagnosis and Management of Immunotherapy Related Endocrinopathies - Venessa Tsang
• Managing patients with immune-related side effects – The nurse’s role - Donna Milne
• The role of the pharmacist in the management of immune-related toxicities - Jim Siderov

• Using data to drive change in breast cancer care - Tim Shaw
• Implementing Cerner Oncology in a metropolitan cancer service: the process and lessons learnt - Richard Khor
• An enterprise-wide analytics strategy to drive change in cancer care delivery and research - Dana Rollison
• Cancer Institute NSW’s vision for integrating data for cancer research: the role of registries. - David Currow
• Just where is data that is relevant to clinical teams hidden? Building a useful map - Emily Stone

International speaker: Dr Allison Welsh, Senior Scientist, Genomic Science and Research, Foundation Medicine Inc. Cambridge, USA  

More information coming soon